Skip to main content

Table 1 Adverse Events and Clinical Outcomes of DAB/IL2 Administration to Melanoma Patients

From: Transient T cell depletion causes regression of melanoma metastases

ID Age M/F Stage Cycles Adverse Events (grade) Outcome(s) HLA-A2* 0201 CD8+ T Cells
P1 50 F IV 2 Erythema (1) Progressive disease - Not applicable
P2 78 M IV 3 Weakness (1) Progressive Disease - Not applicable
P3 58 M IV 4 None Mesenteric & Hepatic Regressions (PR) - Not applicable
P4 66 F IV 1 None Progressive Disease - Not applicable
P5 72 M IV 2 Pain at tumor site (1) R. Hilar and Colon Regressions (PR) - Not applicable
P6 63 M IV 2 None Progressive Disease - Not applicable
P7 67 M IV 4 None Progressive Disease + MART1+Tyr+
P8 58 F IV 4 None IM & SC Regressions (PR) - Not applicable
P9 46 M IV 4 None Inguinal Regression + MART1+g100+ Tyr+
P10 35 F IV 3 None Progressive Disease + Negative
P11 54 M IV 2 None Progressive Disease + Negative
P12 79 M IV 2 Dermatitis (2) Stable Disease - Not applicable
P13 72 M IV 1 Dehydration (2) Progressive Disease - Not applicable
P14 61 M IV 4 Vitiligo (1) Pulmonary, Hepatic, LN & SC Regressions (PR) + MART1+
P15 46 F IV 4 None Progressive Disease + Negative
P16 68 F IV 4 Arthritis (2) Dermatitis (1) Progressive Disease + MART1+g100+ Tyr+